Bank of America Corporate, Investment Banking Chief to Depart 
 

Bank of America Corp. corporate and investment banking head Christian Meissner is leaving the bank, according to an internal memo reviewed by The Wall Street Journal.

 
Profit Repatriation Slows in the Second Quarter After Tax Overhaul 
 

U.S. companies repatriated $169.5 billion in foreign profits between April and June-more than in most recent periods, but underscoring a cautious approach to shifting huge sums across borders.

 
Bank of America to Pay $30 Million in Benchmark-Manipulation Settlement 
 

Bank of America will pay $30 million as part of a settlement with the CFTC related to charges it tried to manipulate a benchmark for interest-rate products.

 
Biggest U.S. Public Pension Looks to China for New Investment Chief 
 

An official with China's foreign-exchange regulator is the lead candidate to become next investment chief of the largest U.S. public pension fund.

 
EU Starts Preliminary Probe of Amazon's Treatment of Merchants 
 

European Union antitrust authorities have opened a preliminary investigation into Amazon.com's treatment of other merchants that sell products using its platform, starting a new regulatory front against an American tech giant.

 
Goldman Sachs Nears Deal to Spin Off 'Simon' App 
 

Goldman Sachs is nearing a deal to spin off its three-year-old app that sells complex investment products, the bank's latest bid to profit from its internal technology.

 
BuzzFeed Cuts Podcast Team 
 

BuzzFeed News is putting its podcasting ambitions on pause.

 
Apple's New Strategy: Sell Pricier iPhones First 
 

For the second straight year, Apple is starting to sell its new iPhone models at different times-but this time, the lag reflects a staggered production timeline set by the tech giant rather than manufacturing issues it experienced last year.

 
Deutsche Bank Senior Banker Advised Bosses to Consider Breakup 
 

A former senior investment banker at Deutsche Bank recommended earlier this year that the troubled German lender consider breaking itself up to address its persistent competitive weaknesses.

 
Novartis' CAR-T Drug Hits First Setback in Europe 
 

Novartis' immunotherapy Kymriah is too expensive to be recommended for use in adults with B-cell lymphoma that have relapsed or haven't responded to first-line treatment, a U.K. regulator said.

 
 

(END) Dow Jones Newswires

September 19, 2018 21:15 ET (01:15 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.